Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis.
Cunniffe NG, Gunter SJ, Brown M, Burge SW, Coyle C, De Soyza A, Dymond T, Esmail H, Francis DP, Galloway J, Galloway JB, Gkrania-Klotsas E, Greenaway J, Katritsis G, Kanagaratnam P, Knolle MD, Leonard K, McIntyre ZC, Prudon B, Rampling T, Torok ME, Warne B, Yates M, Matheson NJ, Su L, Villar S, Stewart GD, Toshner M. Cunniffe NG, et al. BMJ Open. 2020 Oct 5;10(10):e044566. doi: 10.1136/bmjopen-2020-044566. BMJ Open. 2020. PMID: 33020111 Free PMC article.
Visual outcome measures in clinical trials of remyelinating drugs.
Riboni-Verri G, Chen BS, McMurran CE, Halliwell GJ, Brown JWL, Coles AJ, Cunniffe NG. Riboni-Verri G, et al. Among authors: cunniffe ng. BMJ Neurol Open. 2024 Feb 19;6(1):e000560. doi: 10.1136/bmjno-2023-000560. eCollection 2024. BMJ Neurol Open. 2024. PMID: 38389586 Free PMC article. Review.
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, Ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Moran C, Flynn PD, Michell AW, Franklin RJM, Chandran S, Altmann DR, Chard DT, Connick P, Coles AJ. Brown JWL, et al. Among authors: cunniffe ng. Lancet Neurol. 2021 Sep;20(9):709-720. doi: 10.1016/S1474-4422(21)00179-4. Lancet Neurol. 2021. PMID: 34418398 Clinical Trial.
Promoting remyelination in multiple sclerosis.
Cunniffe N, Coles A. Cunniffe N, et al. J Neurol. 2021 Jan;268(1):30-44. doi: 10.1007/s00415-019-09421-x. Epub 2019 Jun 12. J Neurol. 2021. PMID: 31190170 Free PMC article. Review.
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M, Fitzgerald D, de la Fuente AG, Giovannoni G, Gray E, Hazlehurst L, Kapoor R, Kaur R, Kozlowski D, Lumicisi B, Mahad D, Neumann B, Palmer A, Peruzzotti-Jametti L, Pluchino S, Robertson J, Rothaul A, Shellard L, Smith KJ, Wilkins A, Williams A, Coles A. Cunniffe N, et al. J Neurol Neurosurg Psychiatry. 2021 Mar;92(3):295-302. doi: 10.1136/jnnp-2020-324286. Epub 2020 Nov 12. J Neurol Neurosurg Psychiatry. 2021. PMID: 33184094
Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.
McMurran CE, Mukherjee T, Brown JWL, Michell AW, Chard DT, Franklin RJM, Coles AJ, Cunniffe NG. McMurran CE, et al. Among authors: cunniffe ng. Ann Clin Transl Neurol. 2022 Jul;9(7):1090-1094. doi: 10.1002/acn3.51595. Epub 2022 May 19. Ann Clin Transl Neurol. 2022. PMID: 35587315 Free PMC article.
18 results